Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
181-195 of 210
Alzheimer’s Disease: What’s The Latest Research?
NeuroFrontiersAlzheimer’s Disease: What’s The Latest Research?
Diving into the Debate Surrounding Aducanumab for Alzheimer’s
NeuroFrontiersDiving into the Debate Surrounding Aducanumab for Alzheimer’s
Investigating the Impact of Mobile Stroke Units
NeuroFrontiersInvestigating the Impact of Mobile Stroke Units
Investigating the Potential Link Between Epstein-Barr Virus & MS
NeuroFrontiersInvestigating the Potential Link Between Epstein-Barr Virus & MS
Keys to Closing the Gender Gap in Stroke Trials
NeuroFrontiersKeys to Closing the Gender Gap in Stroke Trials
Diagnosing Mental Illness with the Perspectives Approach
NeuroFrontiersDiagnosing Mental Illness with the Perspectives Approach
- advertisement
Seeking Out Symptoms of Broken Heart Syndrome
NeuroFrontiersSeeking Out Symptoms of Broken Heart Syndrome
The Future of Restoring Functionality in Stroke Survivors
NeuroFrontiersThe Future of Restoring Functionality in Stroke Survivors
Refocusing Our Efforts on Advancing Technology to Help Stroke Survivors
NeuroFrontiersRefocusing Our Efforts on Advancing Technology to Help Stroke Survivors
Treatment of Progressive MS: Why, Who, When, How
Global Neurology AcademyTreatment of Progressive MS: Why, Who, When, How
SPECIAL REPORT: Expert Opinion on New MS Drug Approval
Global Neurology AcademySPECIAL REPORT: Expert Opinion on New MS Drug Approval
- advertisement
Now Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
Global Neurology AcademyNow Approved in Europe: First Oral Short-Course Treatment for Highly Active Relapsing MS
Cladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
Global Neurology AcademyCladribine Receives Positive CHMP Opinion for Relapsing MS Treatment
The Diagnostic Challenges of Spinal Cord Lesions in MS
CME/CEThe Diagnostic Challenges of Spinal Cord Lesions in MS























































